Azome Therapeutics
Azome Therapeutics is developing selective antagonists of the NLRP3 inflammasome to target severe inflammatory diseases such as Acute Respiratory Distress Syndrome and Bronchopulmonary Dysplasia. Their lead candidate, AZM-152, inhibits a key priming signal in the NLRP3 pathway, addressing significant unmet medical needs in conditions with limited treatment options.
- Biotechnology
Funding
Founders
Product
Problem
Severe inflammatory pulmonary diseases like Acute Respiratory Distress Syndrome (ARDS), Bronchopulmonary Dysplasia (BPD), and severe viral pneumonia have limited effective preventative or therapeutic treatments. These conditions lead to high mortality rates, extended ICU stays, and long-term health complications, placing a significant burden on patients and healthcare systems.
Solution
Azome Therapeutics is developing selective antagonists of the NLRP3 inflammasome to treat severe inflammatory diseases. Their lead candidate, AZM-152, is a RHAMM-derived antagonist that inhibits a key upstream priming signal involved in the aberrant activation of the NLRP3 inflammatory cascade. By intercepting the activation of the NLRP3 inflammasome, Azome aims to address the unmet needs in conditions such as ARDS, BPD, Idiopathic Pulmonary Fibrosis (IPF), and severe viral pneumonia. The company's drug discovery platform focuses on developing treatments for a wide variety of diseases where the NLRP3 inflammasome plays a critical role.
Target Audience
The primary target audience includes patients suffering from severe inflammatory pulmonary diseases such as ARDS, BPD, and severe viral pneumonia, as well as healthcare providers and researchers seeking new therapeutic options.
Features
- AZM-152: A RHAMM-derived antagonist targeting a key priming signal in the NLRP3 pathway.
- Selective antagonism of the NLRP3 inflammasome to reduce inflammation.
- Focus on severe inflammatory pulmonary diseases with limited treatment options.
- Potential application in Acute Respiratory Distress Syndrome (ARDS).
- Potential application in Bronchopulmonary Dysplasia (BPD).
- Potential application in Idiopathic Pulmonary Fibrosis (IPF).
- Potential application in Severe Viral Pneumonia.